News about "ENHANZE drug delivery technology "

Acumen Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug

Acumen Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug

Acumen Pharmaceuticals, Inc. has announced that the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison study.

ENHANZE Drug Delivery Technology | 03/08/2024 | By Aishwarya 133


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members